in Liquid Biopsy: The Diagnostic and Prognostic Promise for Colorectal Cancer and Adenomas?

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2023 Aug 21

PMID 37601809

Authors

Klara Cervena

Anna Siskova

Jiri Jungwirth

Marin Volaric

Jan Kral

Pavel Kohout

Miroslav Levy

Veronika Vymetalkova

Affiliations

Soon will be listed here.

Abstract

Introduction: The development of colorectal cancer (CRC) is a multistep process accompanied by the accumulation of mutations that start from specific precancerous lesion - colorectal adenomas (CA). CRC incidence and mortality can be reduced by the early identification of these neoplasm. Colonoscopy is the most widely used screening method for CRC identification. Nowadays, clinical research interest is shifting to the use of liquid biopsy that may help with the early diagnosis of CA and CRC. In our previous study, we identified long non-coding RNA gene amplification associated with the development of CA.

Methods: This study aimed to describe the potential of expression levels in the adenoma tissue of patients used in the previous study by real-time qPCR. Furthermore, we analysed the plasma samples of an independent group of patients with CA (n=97), CRC (n=101), and cancer-free individuals (CFI, n=48).

Results: There was no difference in the expression level between CA patients with or without amplification. However, the plasma expression levels were significantly upregulated in patients with CRC and CA compared to CFI (for both p<0.001). Moreover, a correlation between expression and histological types of adenomas was identified- high-CRC-risk adenomas also displayed the highest expression levels. Furthermore, in CRC patients, levels were associated with a response to therapy.

Conclusion: expression levels could serve as a promising circulating biomarker for early CA and CRC diagnosis, and even as a predictor of therapy response in CRC patients.

References

Gonzalez-Kozlova E . Molecular Profiling of Liquid Biopsies for Precision Oncology. Adv Exp Med Biol. 2022; 1361:235-247. DOI: 10.1007/978-3-030-91836-1_13. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Kim S, Kim H, Park H . Adverse events related to colonoscopy: Global trends and future challenges. World J Gastroenterol. 2019; 25(2):190-204. PMC: 6337013. DOI: 10.3748/wjg.v25.i2.190. View

Guo J, Ding Y, Yang H, Guo H, Zhou X, Chen X . Aberrant expression of lncRNA MALAT1 modulates radioresistance in colorectal cancer in vitro via miR-101-3p sponging. Exp Mol Pathol. 2020; 115:104448. DOI: 10.1016/j.yexmp.2020.104448. View

Ji Q, Cai G, Liu X, Zhang Y, Wang Y, Zhou L . MALAT1 regulates the transcriptional and translational levels of proto-oncogene RUNX2 in colorectal cancer metastasis. Cell Death Dis. 2019; 10(6):378. PMC: 6522477. DOI: 10.1038/s41419-019-1598-x. View

Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider P . MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003; 22(39):8031-41. DOI: 10.1038/sj.onc.1206928. View

Kyula J, Van Schaeybroeck S, Doherty J, Fenning C, Longley D, Johnston P . Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin Cancer Res. 2010; 16(13):3378-89. PMC: 2896550. DOI: 10.1158/1078-0432.CCR-10-0014. View

Li J, Ma W, Zeng P, Wang J, Geng B, Yang J . LncTar: a tool for predicting the RNA targets of long noncoding RNAs. Brief Bioinform. 2014; 16(5):806-12. DOI: 10.1093/bib/bbu048. View

Tang Y, Xiao G, Chen Y, Deng Y . LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling. Anticancer Drugs. 2018; 29(8):725-735. DOI: 10.1097/CAD.0000000000000650. View

10.

Jass J . Gastrointestinal polyposes: clinical, pathological and molecular features. Gastroenterol Clin North Am. 2007; 36(4):927-46, viii. DOI: 10.1016/j.gtc.2007.08.009. View

11.

Yang Q, Zheng W, Shen Z, Huang G, Yang G . MicroRNA Binding Site Polymorphisms of the Long-Chain Noncoding RNA are Associated with Risk and Prognosis of Colorectal Cancer in Chinese Han Population. Genet Test Mol Biomarkers. 2020; 24(5):239-248. DOI: 10.1089/gtmb.2020.0013. View

12.

Rubio C, Jaramillo E, Lindblom A, Fogt F . Classification of colorectal polyps: guidelines for the endoscopist. Endoscopy. 2002; 34(3):226-36. DOI: 10.1055/s-2002-20296. View

13.

Chaleshi V, Irani S, Alebouyeh M, Mirfakhraie R, Aghdaei H . Association of lncRNA-p53 regulatory network (lincRNA-p21, lincRNA-ROR and MALAT1) and p53 with the clinicopathological features of colorectal primary lesions and tumors. Oncol Lett. 2020; 19(6):3937-3949. PMC: 7204634. DOI: 10.3892/ol.2020.11518. View

14.

Lone S, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S . Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022; 21(1):79. PMC: 8932066. DOI: 10.1186/s12943-022-01543-7. View

15.

Wu S, Sun H, Wang Y, Yang X, Meng Q, Yang H . MALAT1 rs664589 Polymorphism Inhibits Binding to miR-194-5p, Contributing to Colorectal Cancer Risk, Growth, and Metastasis. Cancer Res. 2019; 79(20):5432-5441. DOI: 10.1158/0008-5472.CAN-19-0773. View

16.

Siddique H, Al-Ghafari A, Choudhry H, AlTurki S, Alshaibi H, Al Doghaither H . Long Noncoding RNAs as Prognostic Markers for Colorectal Cancer in Saudi Patients. Genet Test Mol Biomarkers. 2019; 23(8):509-514. DOI: 10.1089/gtmb.2018.0308. View

17.

Liu Y, Yin Z, Lu P, Ma Y, Luo B, Xiang L . Lung Carcinoma Cells Secrete Exosomal MALAT1 to Inhibit Dendritic Cell Phagocytosis, Inflammatory Response, Costimulatory Molecule Expression and Promote Dendritic Cell Autophagy via AKT/mTOR Pathway. Onco Targets Ther. 2020; 13:10693-10705. PMC: 7586126. DOI: 10.2147/OTT.S256669. View

18.

Yang L, Lin C, Liu W, Zhang J, Ohgi K, Grinstein J . ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell. 2011; 147(4):773-88. PMC: 3297197. DOI: 10.1016/j.cell.2011.08.054. View

19.

Yue X, Wu W, Dong M, Guo M . LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570-3p. Biomed J. 2022; 44(6 Suppl 2):S296-S304. PMC: 9068547. DOI: 10.1016/j.bj.2020.11.002. View

20.

Arun G, Aggarwal D, Spector D . Long Non-Coding RNA: Functional Implications. Noncoding RNA. 2020; 6(2). PMC: 7344863. DOI: 10.3390/ncrna6020022. View